Market Cap 2.08B
Revenue (ttm) 184.42M
Net Income (ttm) -6.89M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3.74%
Debt to Equity Ratio 0.00
Volume 586,000
Avg Vol 775,198
Day's Range N/A - N/A
Shares Out 62.27M
Stochastic %K 4%
Beta 1.22
Analysts Strong Sell
Price Target $45.07

Company Profile

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational n...

Industry: Biotechnology
Sector: Healthcare
Phone: 781 430 8200
Address:
45 Wiggins Avenue, Bedford, United States
GorillaTrades
GorillaTrades Apr. 17 at 7:03 PM
Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Stoke Therapeutics $STOK +6.6%, NVIDIA $NVDA +6.5%, and Celcuity $CELC +4.6%
0 · Reply
GorillaTrades
GorillaTrades Apr. 10 at 7:37 PM
Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Stoke Therapeutics $STOK +6.7%, Celcuity $CELC +3.6%, and Cincinnati Financial $CINF +2.5%
0 · Reply
Doozio
Doozio Apr. 10 at 1:05 AM
$IWM $SMH $XBI how long until they go from fear to walking ENTA da weekend chasing $STTK s and $STOK s.
0 · Reply
NorthStarStats
NorthStarStats Apr. 8 at 8:39 PM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $FRT Score 100, $ANET Score 98, $ENTG Score 98, $STOK Score 98, $ASND Score 98
0 · Reply
Doozio
Doozio Mar. 31 at 2:01 PM
$XBI list of biotech $STOK s that $AUPH to $ASND after this 🐑 correction.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 26 at 7:00 PM
$STOK Q4 '25 Earnings Results & Recap Stoke Therapeutics expects its cash, cash equivalents, and marketable securities of approximately $390.9M as of December 31, 2025, will fund operations into 2028, and anticipates pivotal Phase 3 data for zorevunersen in mid-2027.
0 · Reply
ObeCalp
ObeCalp Mar. 26 at 5:59 PM
$STOK Of course, I buy when green... and shortly after it goes red. Yay, me.
0 · Reply
Quantumup
Quantumup Mar. 20 at 11:53 AM
Canaccord Genuity⬆️ $STOK's PT to $60 from $36 and reiterated at a Buy rating. $BIIB $PRAX DRUG UCBJY JAZZ HLUBF HLBBF Here's what Canaccord Genuity had to say in its note to investors: https://x.com/Quantumup1/status/2034960529656029691?s=20
0 · Reply
danaos
danaos Mar. 19 at 1:04 AM
$STOK Price Target $25 (shortterm)
0 · Reply
LadsAndGents
LadsAndGents Mar. 9 at 2:21 PM
$STOK why don’t just buy this out
0 · Reply
Latest News on STOK
Stoke Therapeutics Earnings Call Transcript: Q3 2025

Nov 4, 2025, 4:30 PM EST - 6 months ago

Stoke Therapeutics Earnings Call Transcript: Q3 2025


Stoke Therapeutics Earnings Call Transcript: Q2 2025

Aug 12, 2025, 4:30 PM EDT - 9 months ago

Stoke Therapeutics Earnings Call Transcript: Q2 2025


Stoke Therapeutics Stock Slips as CEO Steps Down

Mar 18, 2025, 12:56 PM EDT - 1 year ago

Stoke Therapeutics Stock Slips as CEO Steps Down


Stoke Therapeutics Announces CEO Transition

Mar 18, 2025, 6:58 AM EDT - 1 year ago

Stoke Therapeutics Announces CEO Transition


Stoke Therapeutics Transcript: Status Update

Dec 9, 2024, 8:30 AM EST - 1 year ago

Stoke Therapeutics Transcript: Status Update


Stoke Therapeutics Transcript: Study Update

Jul 25, 2023, 8:00 AM EDT - 3 years ago

Stoke Therapeutics Transcript: Study Update


Stoke Therapeutics Transcript: Study Update

Nov 14, 2022, 8:30 AM EST - 3 years ago

Stoke Therapeutics Transcript: Study Update


GorillaTrades
GorillaTrades Apr. 17 at 7:03 PM
Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Stoke Therapeutics $STOK +6.6%, NVIDIA $NVDA +6.5%, and Celcuity $CELC +4.6%
0 · Reply
GorillaTrades
GorillaTrades Apr. 10 at 7:37 PM
Top 3 #momentum #stocks In The GorillaTrades #portfolio This Week: Stoke Therapeutics $STOK +6.7%, Celcuity $CELC +3.6%, and Cincinnati Financial $CINF +2.5%
0 · Reply
Doozio
Doozio Apr. 10 at 1:05 AM
$IWM $SMH $XBI how long until they go from fear to walking ENTA da weekend chasing $STTK s and $STOK s.
0 · Reply
NorthStarStats
NorthStarStats Apr. 8 at 8:39 PM
Output from a custom NorthStarStats momentum scanner highlighting stocks with strengthening price structure and momentum. Setups to watch and study — not trade recommendations. $FRT Score 100, $ANET Score 98, $ENTG Score 98, $STOK Score 98, $ASND Score 98
0 · Reply
Doozio
Doozio Mar. 31 at 2:01 PM
$XBI list of biotech $STOK s that $AUPH to $ASND after this 🐑 correction.
0 · Reply
StocktwitsEarnings
StocktwitsEarnings Mar. 26 at 7:00 PM
$STOK Q4 '25 Earnings Results & Recap Stoke Therapeutics expects its cash, cash equivalents, and marketable securities of approximately $390.9M as of December 31, 2025, will fund operations into 2028, and anticipates pivotal Phase 3 data for zorevunersen in mid-2027.
0 · Reply
ObeCalp
ObeCalp Mar. 26 at 5:59 PM
$STOK Of course, I buy when green... and shortly after it goes red. Yay, me.
0 · Reply
Quantumup
Quantumup Mar. 20 at 11:53 AM
Canaccord Genuity⬆️ $STOK's PT to $60 from $36 and reiterated at a Buy rating. $BIIB $PRAX DRUG UCBJY JAZZ HLUBF HLBBF Here's what Canaccord Genuity had to say in its note to investors: https://x.com/Quantumup1/status/2034960529656029691?s=20
0 · Reply
danaos
danaos Mar. 19 at 1:04 AM
$STOK Price Target $25 (shortterm)
0 · Reply
LadsAndGents
LadsAndGents Mar. 9 at 2:21 PM
$STOK why don’t just buy this out
0 · Reply
janed102
janed102 Mar. 5 at 8:24 AM
$STOK https://www.nejm.org/doi/full/10.1056/NEJMoa2506295
0 · Reply
janed102
janed102 Mar. 5 at 8:22 AM
$STOK https://www.bbc.co.uk/news/articles/c3rzj9jy9e8o
0 · Reply
OfficialStocktwitsUser
OfficialStocktwitsUser Mar. 2 at 8:37 PM
$STOK RSI: 77.18, MACD: 1.4185 Vol: 2.14, MA20: 33.36, MA50: 32.12 🔴 SELL - Downtrend 👉 https://quantumstockalerts.com Disclaimer: I am not a financial advisor. This post reflects personal analysis and opinions only. Please do your own research before investing or trading.
0 · Reply
MK724
MK724 Mar. 2 at 5:09 PM
$STOK what’s the next resistance?
0 · Reply
BillionerOfKing
BillionerOfKing Feb. 18 at 6:02 PM
$STOK Current Stock Price: $31.32 Contracts to trade: $30.0 STOK Feb 20 2026 Call Entry: $0.25 Exit: $0.41 ROI: 63% Hold ~28 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
0 · Reply
ValuationExpert
ValuationExpert Feb. 18 at 4:38 PM
$STOK Stoke Therapeutics focuses on RNA-based therapies. Clinical data drives valuation. Cash runway supports development.
0 · Reply
ClinicalTrialsDaily
ClinicalTrialsDaily Feb. 12 at 7:13 PM
$STOK Clinical pivot point: STK-002 OSPREY trial vs SOC $SANN (Idebenone). Differentiation: 1. SOC = Metabolic bandaid (Oral) 2. STK-002 = Genetic fix (IVT ASO) Key Risk: Ocular inflammation (Endophthalmitis). ADOA is slowly progressive, so safety bar is higher than LHON. Structural RNFL endpoints > VA for early signal. Watch Q4 2026 data. $PYC Read more: www.clinicaltrialsdaily.com/stk-002-adoa-disease-modifying-potential/
0 · Reply